FTC Settles Charges Against Concordia, Par Over Anticompetitive Practices

The FTC has given its final approval to settle charges against Concordia Pharmaceuticals and Par Pharmaceutical alleging they colluded to stop generic versions of Kapvay, an ADHD drug.

Under the terms of the settlement, the companies are barred from trying to bar or delay the entry of an authorized generic version of Kapvay (clonidine) following the expiration of patents covering the drug. The FTC approved the settlement — first announced in August — in a 4-0 vote following a public comment period.

The two companies were the sole marketers of generic Kapvay until May 15. They agreed not to compete, with Concordia declining to sell an authorized generic version of Kapvay in exchange for a share of Par’s revenues.